Background: The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of 90%. However, some retrospective studies reported a 10-y RFS of 81%-86% and suggested benefit from adjuvant systemic therapy.Methods: To evaluate the variables that determined the choice of adjuvant chemotherapy and the type of chemotherapy delivered in pT1a-pT1b BC, we analysed the small tumours enrolled in the NEMESI study.Results: Out of 1,894 patients with pathological stage I-II BC enrolled in NEMESI, 402 (21.2%) were pT1a-pT1b. Adjuvant chemotherapy was delivered in 127/402 (31.59%). Younger age, grading G3, high proliferative index, ER-negative and HER2-positive status were significantly associated with the decision to administer adjuvant chemotherapy. An anthracycline without taxane regimen was administered in 59.1% of patients, anthracycline with taxane in 24.4%, a CMF-like regimen in 14.2% and taxane in 2.4%. Adjuvant chemotherapy was administered in 88.4% triple-negative and 73.46% HER2-positive pT1a-pT1b BC. Adjuvant trastuzumab was delivered in 30/49 HER2-positive BC (61.2%).Conclusions: Adjuvant chemotherapy was delivered in 31.59% T1a-pT1b BC treated at 63 Italian oncological centres from January 2008 to June 2008. The choice to deliver chemotherapy was based on biological prognostic factors. Anthracycline-based chemotherapy was administered in 83.5% patients.
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma : results from the NEMESI study / S. Gori, M. Clavarezza, S. Siena, J. Foglietta, E. Tarenzi, M. Giordano, A. Molino, C. Graiff, V. Fusco, O. Alabiso, E. Baldini, T. Gamucci, G. Altavilla, D. Dondi, M. Venturini. - In: BMC CANCER. - ISSN 1471-2407. - 12:1(2012 Apr 30), pp. 158.1-158.11.
|Titolo:||Adjuvant chemotherapy of pT1a and pT1b breast carcinoma : results from the NEMESI study|
|Parole Chiave:||Adjuvant chemotherapy; Adjuvant hormonal therapy; PT1a and pT1b breast cancer; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Menopause; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Young Adult; Oncology; Cancer Research; Genetics|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||30-apr-2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/1471-2407-12-158|
|Appare nelle tipologie:||01 - Articolo su periodico|